[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508178":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":35,"collaborators":39,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":26,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":26,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":26,"overallStatus":63,"whyStopped":26,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":26},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"control group","ACTIVE_COMPARATOR","This group will take doxycycline 100 mg twice daily",[13],"Drug: Doxycyclin",{"label":15,"type":10,"description":16,"interventionNames":17},"Comparative group","This group will take doxycycline 100 mg twice daily, pentoxifylline 400 mg twice daily, and nitazoxanide 500 mg twice daily.",[13,18,19],"Drug: Pentoxifylline","Drug: Nitazoxanide 500Mg Oral Tablet",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Doxycyclin","Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated",[15,9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Pentoxifylline","Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity",[15],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Nitazoxanide 500Mg Oral Tablet","Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections",[15],{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Mostafa Bahaa","Teaching assisstant",[40],{"name":41,"class":42},"Mostafa Mahmoud Bahaa Clinical Pharmacy Department, Horus University, New Damietta, Egypt","UNKNOWN","100508178","phase-2-combination-therapy-between-doxycycline-pentoxifylline-and-nitazoxanide-in-sexually-active-men-100508178",false,"NCT05897034","Combination Therapy Between Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men","Clinical Study to Investigate the Effect of Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men","Inclusion Criteria:\n\n* Individuals aged \\> 18 years were eligible for participation if they had a diagnosis of untreated gonorrhea and chlamydia. The untreated status was defined as no antibiotic taken in the previous 28 days to treat gonorrhea and chlamydia.\n\nExclusion Criteria:\n\n* known contraindications or hypersensitivity to doxycycline, pentoxifylline, and nitazoxanide.\n\ngonorrhea with complications, such as pelvic inflammatory disease or epididymo-orchitis significant renal failure or hepatic failure.","MALE","18 Years","60 Years",{"count":54,"type":55},100,"ESTIMATED","INTERVENTIONAL",[58,59],"PHASE2","PHASE3","Bacterial sexually transmitted infections (STIs) have been steadily increasing in gay, bisexual, and other men who have sex with men (MSM) over the past 2 decades. While that trend started prior to the introduction of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) in 2012, HIV PrEP has been associated with increases in sexual contacts and decreases in condom use with an resultant acceleration in the increase of bacterial STIs such as gonorrhea, syphilis, and chlamydia.",[62],"Sexually Transmitted Diseases","NOT_YET_RECRUITING","2023-06-08",{"date":66,"type":67},"2023-06-12","ACTUAL",{"date":69,"type":55},"2023-06-20",{"date":71,"type":55},"2028-06-20",{"name":5,"class":6}]